法国赛诺菲的喜保宁怎么样？

Sabril (vigabatrin) is an irreversible GABA transaminase inhibitor that increases GABA levels in the brain and cerebrospinal fluid. Vigabatrin is developed by the French Sanofi Group, the third largest pharmaceutical company in the world and ranked first in Europe. Its business covers more than 100 countries around the world, and currently has approximately 11,000 scientists and 100,000 employees serving the health industry.

How about Vigabatrin from Sanofi France? It is usually used for partial seizures of epilepsy and can also be used in combination with other anti-epileptic drugs to treat refractory epilepsy. It can also be used for children with Lennox-Gastaut syndrome and West syndrome (infant pain syndrome). It is not effective for epileptic seizures and muscle spasms. It needs to be taken under the guidance of a physician.

Vigabatrin has been used in Europe since the 1990s to treat infantile spasms, and its effect is better than ACTH. In 2009, the U.S. FDA approved the drug for infantile spasms in the United States. Currently, the drug has been listed as a first-line drug treatment for infantile spasms in Europe and North America, and may also have a certain effect on drug-refractory complex partial seizures in TSC patients. The side effects of this drug include drowsiness, decreased muscle tone, weight gain, insomnia, etc., but its biggest disadvantage is its impact on visual field. The time from the start of treatment to the remission of epilepsy is about 12-35 days. The probability of visual impairment during this period is relatively low. It is currently believed that if there is no obvious effect after more than 12 weeks of use, discontinuation of the drug can be considered.

Recommended related hot articles: /newsDetail/95633.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.